GeneCode receives record Parkinson’s funding
European Innovation Council Accelerator finances treatment development drive for condition
Read Moreby John Pinching | Jul 6, 2023 | News | 0
European Innovation Council Accelerator finances treatment development drive for condition
Read Moreby John Pinching | Feb 28, 2023 | News | 0
Research into modified RNA messages could help treat diseases and develop new therapies
Read Moreby John Pinching | Feb 23, 2023 | News | 0
Next phase of Newel Health’s digital therapeutics solution for Parkinson’s disease gains vital grant
Read Moreby Anna Smith | Feb 28, 2020 | News | 0
The companies have detailed plans to leverage Sangamo’s proprietary zinc finger protein (ZFP) technology.
Read Moreby Anna Smith | Jan 15, 2020 | News | 0
The results are the latest in a number of recent studies which have found a link between brain function and the digestive system.
Read Moreby Anna Smith | Oct 17, 2019 | News | 0
Only half of patients who are diagnosed as young onset patients are offered a genetic test on diagnosis.
Read Moreby Anna Smith | Aug 9, 2019 | News | 0
After the acquisition, Bayer will own full rights to BlueRock Therapeutics’ CELL+GENE platform.
Read Moreby Anna Smith | Jul 31, 2019 | News | 0
It has also announced the appointment of the company’s new general manager, Craig Bowen.
Read Moreby Anna Smith | Jul 1, 2019 | News | 0
The charity is partnering with NRG Therapeutics Ltd to discover and develop a potential drug that could safeguard dopamine cells.
Read Moreby Anna Smith | Jun 28, 2019 | News | 0
The collaboration will initially accelerate C4X Discovery’s Parkinson’s disease drug discovery pipeline.
Read Moreby Anna Smith | Jan 31, 2019 | News | 0
Parkinson’s UK says it intends to invest a further £1.5 million into its drug discovery programme aiming to develop novel gene transcription modulators for Parkinson’s.
Read Moreby Selina McKee | Sep 25, 2018 | News | 0
Virtual biotech Keapstone Therapeutics is in line for a further £1 million investment from Parkinson’s UK to move forward its innovative disease-modifying therapeutic approach to motor neuron disease (MND) and Parkinson’s.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
